RDIF and Serum Institute agree manufacturing deal for Sputnik V

13 July 2021
vaccine_sputnik_big

A key partnership between the Russian backers of the Sputnik V coronavirus vaccine and the Serum Institute of India (SII) could pave the way for broader immunization of people in developing countries.

The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, said the first batch of Sputnik V vaccine is expected to be produced at SII's facilities as soon as September.

The SII is an important philanthropic organization, as well as the world's largest manufacturer of coronavirus vaccines, and a vital participant in the global fight against the disease.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical